Abstract
Lipid-based drug delivery systems has become a popular choice for oral delivery of lipophilic drugs with dissolution rate limited oral absorption. Lipids are known to enhance oral bioavailability of poorly water-soluble drugs in multiple ways like facilitating dissolution as micellar solution, enhancing the lymphatic uptake and acting as inhibitors of efflux transporters. Lipid nanoparticles are matrix type lipid-based carrier systems which can effectively encapsulate both lipophilic and hydrophilic drugs. Lipid nanoparticles namely solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are versatile drug delivery system and can be used for multiple routes of delivery like parenteral, topical, ocular, transdermal, and oral. Lipid nanoparticles are particularly attractive vehicles for peroral delivery of drugs with oral bioavailability problems as they are composed of lipid excipients which are cheap, easily available, and non-toxic; manufacturing technique is simple and readily scalable for large-scale production; the formulations provide controlled release of active components and have no stability issue. A large number of drugs have been incorporated into lipid nanoparticles with the objective of overcoming their poor oral bioavailability. This review tries to assess the potential of lipid nanoparticles for enhancing the oral bioavailability of drugs with permeability limited oral absorption such as drugs belonging to class IV of Biopharmaceutic Classification System (BCS) and protein and peptide drugs and also discusses the mechanism behind the bioavailability enhancement and safety issues related to such delivery systems.
Similar content being viewed by others
References
Amidon GL, Lennernaes H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.
Lipinski CA. Avoiding investment in doomed drugs—is solubility an industry wide problem? Curr Drug Discov. 2001;1:17–9.
Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Exp Op Drug Met Tox. 2008;4:923–39. https://doi.org/10.1517/17425255.4.7.923.
Charman WN, Porter CJ, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86:269–82.
Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs nature reviews. Drug Des Discov. 2007;6:231–48.
Porter CJH, Charman WN. Intestinal lymphatic transport: an update. Adv Drug Deliv Rev. 2001;50:61–80.
Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for Oral drug delivery. Drug Dev Ind Pharm. 2008;34:1394–405.
Müller RH et al., Solid-liquid (semi-solid) lipid particles and method of producing highly concentrated lipid particle dispersions, German patent application. 2000; DE199145203.
Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49(11):1444–7.
Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.V. Administration to rats. Pharmacol Res. 2000;42(4):337–43.
Bhandari RK, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles international. Aust J Pharm. 2013;441(1–2):202–12.
Freitas C, Muller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN®) dispersions. Int J Pharm. 1998;168(2):221–9.
Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN(TM)) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47(2):125–32.
Freitas C, Muller RH. Stability determination of solid lipid nanoparticles (SLN®) in aqueous dispersion after addition of electrolyte. J Microencapsul. 1999;16(1):59–71.
Dingler A, Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul. 2002;19(1): 11–6. 14. Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie. 2001;56(1):61–3.
Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8(11):1407–24. https://doi.org/10.1517/17425247.2011.604311.
Poovi G, Damodharan N. Lipid nanoparticles: a challenging approach for oral delivery of BCS class-II drugs. Future J Pharm Sci. 2018;4(2):191–205.
Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA. 2016;2(3):FSO135. https://doi.org/10.4155/fsoa-2016-0030.
Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv. 2015;22(6):691–700. https://doi.org/10.3109/10717544.2014.898110.
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76. https://doi.org/10.1208/s12249-010-9563-0.
Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48(2–3):223–36.
Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121–8.
Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59:667–76.
Souto EB, Muller RH. Lipid NPs: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol. 2010;197:115–41.
Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drugconjugate (LDC) NPs as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2002;10:387–96.
Jenning V, Lippacher A, Gohla SH. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul. 2002;19(1):1–10.
Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco MR. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie. 1998;53(6):392–6.
Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution patent US5250236. 1993.
Igartua M, Saulnier P, Heurtault B, Pech B, Proust JE, Pedraz JL, et al. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int J Pharm. 2002;233(1–2):149–57.
Bondi ML, Azzolina A, Craparo EF, Lampiasi N, Capuano G, Giammona G, et al. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J Drug Target. 2007;15(4):295–301.
Sjostrom B, Kaplun A, Talmon Y, Cabane B. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm Res. 1995;12(1):39–48.
Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm. 2003;253(1–2):23–38.
Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm. 2003;257(1–2):153–60.
Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm. 2002;239(1–2):121–8.
Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125–31.
Cavalcanti SMT, Nunes C, Costa Lima SA, Soares-Sobrinho JL, Reis S. Optimization of nanostructured lipid carriers for zidovudine delivery using a microwave-assisted production method. Eur J Pharm Sci. 2018;122:22–30. https://doi.org/10.1016/j.ejps.2018.06.017.
Onoue S, Sato H, Ogawa K, Kawabata Y, Mizumoto T, Yuminoki K, et al. Improved dissolution and pharmacokinetic behavior of cyclosporine a using high-energy amorphous solid dispersion approach. Int J Pharm. 2010;399(1–2):94–101.
Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129–34.
Sharma P, Varma MV, Chawla HP, Panchagnula R. Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers. Farmaco. 2005;60(11–12):870–3.
Tjia JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol. 1991;31(3):344–6.
Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989;6(1):40–3.
Wang K, Qi J, Weng T, Tian Z, Lu Y, Hu K, et al. Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomedicine. 2014;9:4991–9. https://doi.org/10.2147/IJN.S72560 eCollection 2014.
Müller RH, Rungea S, Ravelli V, Mehnerta W, Thünemannc AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm. 2006;317(1):82–9.
Rajagopalan N, Chen SC, Chow W. A study of the inclusion complex of amphotericin B with γ-cyclodextrin. Int J Pharm. 1986;29:161–8.
Wu J-Q, Shao K, Wang X, Wang RY, Cao YH, Yu YQ, et al. In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier. Antimicrob Agents Chemother. 2014;58(8):4464–9. https://doi.org/10.1128/AAC.02535-14.
Chaudhari MB, Desai PP, Patel PA. Patravale VB solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module. Drug Deliv Transl Res. 2016;6(4):354–64. https://doi.org/10.1007/s13346-015-0267-6.
Wahlang B, Pawar YB. Bansal AK identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm. 2011;77(2):275–82. https://doi.org/10.1016/j.ejpb.2010.12.006.
Fang M, Jin Y, Bao W, et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomedicine. 2012;7:5395–404. https://doi.org/10.2147/IJN.S36257.
Ji H, Tang J, Li M, Ren J, Zheng N, Wu L. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv. 2016;23(2):459–70. https://doi.org/10.3109/10717544.2014.918677.
Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132–40. https://doi.org/10.1016/j.ejpb.2017.04.013.
Clouser CL, Bonnac L, Mansky LM, Patterson SE. Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antivir Chem Chemother. 2014;23(6):223–30. https://doi.org/10.3851/IMP2682.
Neupane YR, Srivastava M, Ahmad N, Kumar N, Bhatnagar A, Kohli K. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. Int J Pharm. 2014;477(1–2):601–12. https://doi.org/10.1016/j.ijpharm.2014.11.001.
Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class-II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci. 2002;91:719–29.
Khan S, Shaharyar M, Fazil M, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - optimization of production and characterization. Eur J Pharm Biopharm. 2016;108:277–88. https://doi.org/10.1016/j.ejpb.2016.07.017.
Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic Oral bioavailability of etoposide. Pharm Res. 1989;6(5):408–12.
Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci. 2011;43:174–9.
Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A. Des Rieux a, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166(2):115–23.
Beloqui A, Solinís MÁ, des Rieux A, Préat V, Rodríguez-Gascón A. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm. 2014;468(1–2):105–11. https://doi.org/10.1016/j.ijpharm.2014.04.027.
Alex AMR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1–2):11–8. https://doi.org/10.1016/j.ejps.2010.10.002.
Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine. 2012;7:3537–45. https://doi.org/10.2147/IJN.S32880.
Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5:96437–47.
Cho H-J, Park JW, Yoon I-S, Kim D-D. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine. 2014;9:495–504. https://doi.org/10.2147/IJN.S56648.
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031–5.
Pandita D, Ahuja A, Lather V, Dutta T, Velpandian T, Khar RK. Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. Pharmazie. 2011;66(3):171–7.
Pooja D, Kulhari H, Kuncha M, Rachamalla SS, Adams DJ, Bansal V. And SistlaR. Improving efficacy, Oral bioavailability, and delivery of paclitaxel using protein-grafted solid lipid nanoparticles. Mol Pharm. 2016;13(11):3903–12. https://doi.org/10.1021/acs.molpharmaceut.6b00691.
Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000;42(3):225–38.
Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289–300.
Olbrich C, Kayser O, Müller RH. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) – effect of surfactants, storage time and crystallinity. Int J Pharm. 2002;237(1–2):119–28.
Dumont C, Bourgeois S, Fessi H, Jannin V. Lipid-based nanosuspensions for oral delivery of peptides, a critical review. Int J Pharm. 2018;541(1–2):117–35. https://doi.org/10.1016/j.ijpharm.2018.02.038.
Chen C, Fan T, Jin Y, Zhou Z, Yang Y, Zhu X, et al. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids. Nanomedicine (London). 2013;8(7):1085–100. https://doi.org/10.2217/nnm.12.141.
Ansari MJ, Anwer MK, Jamil S, Al-Shdefat R, Ali BE, Ahmad MM, et al. Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. Drug Deliv. 2016;23(6):1972–9. https://doi.org/10.3109/10717544.2015.1039666.
Zhao Y, Huang L. Lipid nanoparticles for gene delivery. Adv Genet. 2014;88:13–36. https://doi.org/10.1016/B978-0-12-800148-6.00002-X.
Ball RL, Bajaj P & Whitehead KA Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract Scientific Reports. 2018; 8:2178. https://doi.org/10.1038/s41598-018-20632-6.
Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125(1):91–7.
Kuksis, A. Absorption of fat soluble vitamins. In: Kuksis A, editor. Fat absorption Vol. 2. Boca Raton: CRC Press. 1987.p-65-86.
Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87–93.
Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000;89(8):967–78.
Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev. 1996;19(2):149–69.
Thomson AB, Schoeller C, Keelan M, Smith L, Clandinin MT. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol. 1993;71(8):531–55.
Shiau YF, Kelemen RJ, Reed MA. Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion. Am J Phys. 1990;259(4 Pt 1):G671–5.
Shiau YF, Levine GM. pH dependence of micellar diffusion and dissociation. Am J Physiol-Gastrointest Liv Physiol. 1980;239(3):G177–82.
Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal lymphatic transport of Halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003;20(9):1460–5.
Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.
Eldridge JH, Hammond CJ, Meulbroeck JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release. 1990;11:205–14.
Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev. 1995;17:129–48.
Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer’s patches. Am J Phys. 1998;275(1 Pt 1):G130–7.
Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res. 1998;15:1160–7.
Raghava KM, Lakshmi PK. Overview of P-glycoprotein inhibitors: a rational outlook. Brazil J Pharm Sci. 2012;48(3):353–67. https://doi.org/10.1590/S1984-82502012000300002.
Varma MVS, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347–59.
Shangguan M, Qi J, Lu Y, Wu W. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure. Int J Pharm. 2015;489(1–2):195–202. https://doi.org/10.1016/j.ijpharm.2015.05.005.
Abuasal BS, Lucas C, Peyton B, Alayoubi A, Nazzal S, Sylvester PW, et al. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids. 2012;47(5):461–9. https://doi.org/10.1007/s11745-012-3655-4.
Severino P, Souto EB, Pinho SC, Santana MHA. Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion. Pharm Dev Technol. 2013;18(3):577–81.
Albrecht K, Bernkop-Schnurch A. Thiomers: forms, functions and applications to nanomedicine. Nanomedicine. 2007;2(1):41–50.
Gradauer K, Dunnhaupt S, Vonach C, et al. Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J Control Release. 2013;165(3):207–15.
Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm. 2015;12(7):2384–95.
Fonte P, Nogueira T, Gehm C, Ferreira D, Sarmento B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res. 2011;1(4):299–308. https://doi.org/10.1007/s13346-011-0023-5.
Sarmento B, Mazzaglia D, Bonferoni MC, Neto AP, Monteiro M, Seabra V. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym. 2011;84(3):919–25.
Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011;1816(2):232–46.
Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005;62(16):1839–49.
Dietz GP. Protection by neuroglobin and cell-penetrating peptide mediated delivery in vivo: a decade of research. Comment on Cai et al: TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol. 2011;227(1):224–31.
Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci. 2010;67(5):715–26.
Kibria G, Hatakeyama H, Harashima H. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int J Pharm. 2011;412(1–2):106–14.
Madani F, Lindberg S, Langel U, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011;2011:1–10. https://doi.org/10.1155/2011/414729.
Järver P, Langel U. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today. 2004;9(9):395–402.
Zhang Z, Lv H, Zhou J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie. 2009;64(9):574–8.
Fan T, Chen C, Guo H, XuJian J, et.al., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm 2014; 88(2):518–528.
Baek J, So J, Shin S, Cho C. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Int J Mol Med. 2012;30:953–9.
Tian C, Asghar S, Wu Y, Chen Z, Jin X, Yin L, et al. Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers. Int J Nanomedicine. 2017;12:7897–911. https://doi.org/10.2147/IJN.S145988.
Tian C, Asghar S, Wu Y, Kambere Amerigos D, Chen Z, Zhang M, et al. N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Drug Deliv. 2017;24(1):1605–16. https://doi.org/10.1080/10717544.2017.1391890.
Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh HJ. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces. 2014;117:21–8. https://doi.org/10.1016/j.colsurfb.2014.01.055.
Doktorovova S, Silva AM, Gaivão I, Souto EB, Teixeira JP, Martins-Lopes P. Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles. Appl Toxicol. 2014;34(4):395–403. https://doi.org/10.1002/jat.2961.
Nassimi M, Schleh C, Lauenstein HD, Hussein R, Lübbers K, Pohlmann G, et al. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal Toxicol. 2009;21(Suppl 1):104–9. https://doi.org/10.1080/08958370903005769.
Li J, Guo X, Liu Z, Okeke CI, Li N, Zhao H, et al. Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev Ind Pharm. 2014;40(7):980–7. https://doi.org/10.3109/03639045.2013.795582.
Petersen S, Steiniger F, Fischer D, Fahr A, Bunjes H. The physical state of lipid nanoparticles influences their effect on in vitro cell viability. Eur J Pharm Biopharm. 2011;79(1):150–61. https://doi.org/10.1016/j.ejpb.2011.03.022.
Rawat MK, Jain A, Singh S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J Pharm Sci. 2011;100(6):2406–17. https://doi.org/10.1002/jps.22454.
D M Ridolfi, P D Marcato, D Machado, R A Silva, G Z Justo and N Durán4. In vitro cytotoxicity assays of solid lipid nanoparticles in epithelial and dermal cells. J of Physics: Conference Series 304. 2011; 012032 doi:https://doi.org/10.1088/1742-6596/304/1/012032.
Severino P, Andreani T, Jäger A, Chaud MV, Santana MH, Silva AM, et al. Solid lipid nanoparticles for hydrophilic biotech drugs: optimization and cell viability studies (Caco-2 & HEPG-2 cell lines). Eur J Med Chem. 2014;81:28–34. https://doi.org/10.1016/j.ejmech.2014.04.084.
Silva AH, Filippin-Monteiro FB, Mattei B, Zanetti-Ramos BG, Creczynski-Pasa TB. In vitro biocompatibility of solid lipid nanoparticles. Sci Total Environ. 2012;432:382–8. https://doi.org/10.1016/j.scitotenv.2012.06.018.
Winter E, Dal Pizzol C, Locatelli C, Crezkynski-Pasa TB. Development and evaluation of lipid nanoparticles for drug delivery: study of toxicity in, vitro and in vivo. J Nanosci Nanotechnol. 2016;16(2):1321–30.
Ong YS, Saiful Yazan L, Ng WK, Noordin MM, Sapuan S, Foo JB, et al. Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice. Int J Nanomedicine. 2016;11:5905–15. https://doi.org/10.2147/IJN.S114205.
Kanwar R, Gradzielski M, Prevost S, Kaur G, Clemens D, Appavou MS, et al. Effect of lipid chain length on nanostructured lipid carriers: comprehensive structural evaluation by scattering techniques. J Colloid Interface Sci. 2018;534:95–104. https://doi.org/10.1016/j.jcis.2018.08.066.
Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14(4):458–62.
How CW, Rasedee A, Abbasalipourkabir R. Characterization and cytotoxicity of nanostructured lipid carriers formulated with olive oil, hydrogenated palm oil, and polysorbate 80. IEEE Trans Nanobioscience. 2013;12(2):72–8. https://doi.org/10.1109/TNB.2012.2232937.
Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr C. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 2004;57(2):155–62.
Saedi A, Rostamizadeh K, Parsa M, Dalali N, Ahmadi N. Preparation and characterization of nanostructured lipid carriers as drug delivery system: influence of liquid lipid types on loading and cytotoxicity. Chem Phys Lipids. 2018;216:65–72. https://doi.org/10.1016/j.chemphyslip.2018.09.007.
Rahman HS, Rasedee A, Othman HH, et al. Acute toxicity study of Zerumbone-loaded nanostructured lipid carrier on BALB/c mice model. BioMed Res International. 2014;563930.
Chen Y, Yuan L, Zhou L, Zhang Z, Cao W, Wu Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine. 2012;7:4581–91. https://doi.org/10.2147/IJN.S34991.
Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, Egea MA, Garcia ML, Souto SB, et al. A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm Dev Technol. 2013;18(3):545–9.
Müller RH, Staufenbiel S, Keck C. Lipid nanoparticles (SLN, NLC) for innovative consumer care & household products. H&PC Today. 2014;9:18–24.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Talegaonkar, S., Bhattacharyya, A. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability. AAPS PharmSciTech 20, 121 (2019). https://doi.org/10.1208/s12249-019-1337-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12249-019-1337-8